Concerns Halt Idenix Hep C Drug
Share
Follow Us
The Editors at Hepatitis Central
August 31, 2012
Because of its likeness to Bristol-Myers’ Hepatitis C drug that was associated with heart problems, Idenix’s IDX19368 has been placed on a clinical hold by the FDA.
Idenix: FDA Places Hepatitis C Treatment on Clinical Hold
Published August 27, 2012
Dow Jones Newswires
Idenix Pharmaceuticals Inc. (IDIX) said the Food and Drug Administration placed a clinical hold on one of its treatments for hepatitis C, the latest setback for the drug developer.
The clinical hold on the treatment–IDX19368–is related to the regulator’s heart-safety concerns about rival Bristol-Myers Squibb Co.’s (BMY) closely watched treatment for the liver disease, which belongs to the same class of drugs–known as nucleotide polymerase inhibitors.
Continue reading this entire article:
http://www.foxbusiness.com/news/2012/08/27/idenix-fda-places-hepatitis-c-treatment-on-clinical-hold/
